{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:04:12Z","timestamp":1791482652680,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cbi.2026.112323","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:11:43Z","timestamp":1788016303000},"page":"112323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Simultaneous determination of bosutinib and its metabolite in rat plasma by UPLC-MS\/MS: Development, validation and application to pharmacokinetic and metabolic stability studies"],"prefix":"10.1016","volume":"439","author":[{"given":"Peiqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-ai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.cbi.2026.112323_bib1","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia: a review","volume":"333","author":"Jabbour","year":"2025","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.cbi.2026.112323_bib2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.cbi.2026.112323_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7150\/ijbs.86305","article-title":"Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"20","author":"Sun","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.cbi.2026.112323_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101196","article-title":"Chronic myeloid leukaemia: biology and therapy","volume":"65","author":"Wang","year":"2024","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.cbi.2026.112323_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41375-022-01736-5","article-title":"Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia","volume":"37","author":"Senapati","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.cbi.2026.112323_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.17849\/insm-52-3-1-7.2","article-title":"Chronic myeloid leukemia - a review of current status","volume":"52","author":"Titcomb","year":"2025","journal-title":"J. Insur. Med."},{"issue":"9","key":"10.1016\/j.cbi.2026.112323_bib7","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"14","key":"10.1016\/j.cbi.2026.112323_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35953","article-title":"Management of chronic myeloid leukemia in 2025","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.cbi.2026.112323_bib9","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.21037\/tcr-24-747","article-title":"Comparative efficacy and safety of first-line tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and network meta-analysis","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl. Cancer Res."},{"issue":"5","key":"10.1016\/j.cbi.2026.112323_bib10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/bjh.18370","article-title":"Treatment of blast phase chronic myeloid leukaemia: a rare and challenging entity","volume":"199","author":"Copland","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.cbi.2026.112323_bib11","first-page":"2738","article-title":"A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia","volume":"141","author":"Krishnan","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cbi.2026.112323_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11095-020-02834-8","article-title":"Physiologically-based pharmacokinetic predictions of the effect of curcumin on metabolism of imatinib and bosutinib: in vitro and in vivo disconnect","volume":"37","author":"Adiwidjaja","year":"2020","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.cbi.2026.112323_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40272-023-00608-4","article-title":"Bosutinib: pediatric first approval","volume":"26","author":"Hoy","year":"2024","journal-title":"Paediatr Drugs"},{"issue":"4","key":"10.1016\/j.cbi.2026.112323_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12185-024-03830-z","article-title":"A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and\/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial)","volume":"120","author":"Ureshino","year":"2024","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.cbi.2026.112323_bib15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s12185-022-03435-4","article-title":"Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study","volume":"116","author":"Ono","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.cbi.2026.112323_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101707","article-title":"Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): a multicentre, open-label, dose-escalation phase 1 trial","volume":"53","author":"Imamura","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"17","key":"10.1016\/j.cbi.2026.112323_bib17","doi-asserted-by":"crossref","first-page":"17981","DOI":"10.1002\/cam4.6439","article-title":"Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"12","author":"Garrett","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.cbi.2026.112323_bib18","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"Administration","year":"2018"},{"key":"10.1016\/j.cbi.2026.112323_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jchromb.2015.09.030","article-title":"A simple method for the determination of Bosutinib in rat plasma by UPLC-MS\/MS","volume":"1004","author":"Xu","year":"2015","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"issue":"2","key":"10.1016\/j.cbi.2026.112323_bib20","first-page":"156","article-title":"Separation techniques: chromatography","volume":"3","author":"Coskun","year":"2016","journal-title":"North Clin Istanb"},{"issue":"1","key":"10.1016\/j.cbi.2026.112323_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jssc.202100534","article-title":"Strategies to circumvent the solvent strength mismatch problem in online comprehensive two-dimensional liquid chromatography","volume":"45","author":"Chapel","year":"2022","journal-title":"J. Separ. Sci."},{"key":"10.1016\/j.cbi.2026.112323_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.464725","article-title":"Theoretical and practical guidelines for solvent dilution between the two dimensions in online comprehensive two-dimensional liquid chromatography","volume":"1718","author":"Aebischer","year":"2024","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.cbi.2026.112323_bib23","article-title":"Effects of three flavonoids on the metabolism of lenvatinib","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.cbi.2026.112323_bib24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/13880209.2021.1871634","article-title":"Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism","volume":"59","author":"Shang","year":"2021","journal-title":"Pharm. Biol."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000927972600431X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000927972600431X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:26:41Z","timestamp":1791232001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000927972600431X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":24,"alternative-id":["S000927972600431X"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2026.112323","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of bosutinib and its metabolite in rat plasma by UPLC-MS\/MS: Development, validation and application to pharmacokinetic and metabolic stability studies","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2026.112323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112323"}}